1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
973 242 0005
https://www.synaptogen.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 5
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Alan J. Tuchman M.D., MBA(FAAN) | CEO & Director | 303,35k | N/A | 1947 |
Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer & Director | 375k | N/A | 1942 |
Mr. Robert Weinstein | CFO, Executive VP, Treasurer & Secretary | 568,92k | N/A | 1960 |
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.